Faculty of Medicine, KU Leuven, B3000 Leuven, Belgium.
Center for Metabolic Diseases, Department of Paediatrics, University Hospitals Leuven, B3000 Leuven, Belgium.
Genes (Basel). 2021 Oct 21;12(11):1658. doi: 10.3390/genes12111658.
PMM2-CDG is a rare disease, causing hypoglycosylation of multiple proteins, hence preventing full functionality. So far, no direct genotype-phenotype correlations have been identified. We carried out a retrospective cohort study on 26 PMM2-CDG patients. We collected the identified genotype, as well as continuous variables indicating the disease severity (based on Nijmegen Pediatric CDG Rating Score or NPCRS) and dichotomous variables reflecting the patients' phenotype. The phenotypic effects of patients' genotype were studied using non-parametric and Chi-Square tests. Seventeen different pathogenic variants have been studied. Variants with zero enzyme activity had no significant impact on the Nijmegen score. Pathogenic variants involving the stabilization/folding domain have a significantly lower total NPCRS ( = 0.017): presence of the p.Cys241Ser mutation had a significantly lower subscore 1,3 and NPCRS ( = 0.04) and thus result in a less severe phenotype. On the other hand, variants involving the dimerization domain, p.Pro113Leu and p.Phe119Leu, resulted in a significantly higher NPCRS score ( = 0.002), which indicates a worse clinical course. These concepts give a better insight in the phenotypic prognosis of PMM2-CDG, according to their molecular base.
PMM2-CDG 是一种罕见疾病,会导致多种蛋白质的低糖化,从而阻止其充分发挥功能。到目前为止,尚未确定直接的基因型-表型相关性。我们对 26 名 PMM2-CDG 患者进行了回顾性队列研究。我们收集了已确定的基因型,以及表明疾病严重程度的连续变量(基于尼梅亨儿科 CDG 评分或 NPCRS)和反映患者表型的二分变量。使用非参数和卡方检验研究了患者基因型的表型效应。研究了 17 种不同的致病性变异。无酶活性的变异对尼梅亨评分没有显著影响。涉及稳定/折叠结构域的致病性变异总 NPCRS 显著降低( = 0.017):存在 p.Cys241Ser 突变的患者,其第 1、3 项和 NPCRS 子评分显著降低( = 0.04),从而表现出较轻的表型。另一方面,涉及二聚化结构域的变异,p.Pro113Leu 和 p.Phe119Leu,则导致 NPCRS 评分显著升高( = 0.002),这表明临床病程更差。这些概念根据其分子基础,更好地了解了 PMM2-CDG 的表型预后。